Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarmishtha De

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2021
The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damageSarmishtha De, Elise G Holvey-Bates, Kala Mahen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2005
VEGF-integrin interplay controls tumor growth and vascularizationSarmishtha De, Olga Razorenova, Noel Patrick McCabe, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2015
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signalSarmishtha De, Hao Zhou, David DeSantis, et al.
British Journal of Cancer|December 1, 2020
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancerDaniel J Lindner, Gary Wildey, Yvonne Parker, et al.
Blood|April 24, 2004
Impaired platelet responses to thrombin and collagen in AKT-1-deficient miceJuhua Chen, Sarmishtha De, Derek S Damron, et al.
Cancer Research|February 15, 2018
The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing <i>NOTCH1</i> Expression and Targeting Tumor-Initiating CellsSarmishtha De, Daniel J Lindner, Claire J Coleman, et al.
The Journal of Biological Chemistry|July 30, 2003
Molecular pathway for cancer metastasis to boneSarmishtha De, Juhua Chen, Natalya V Narizhneva, et al.
Molecular Cancer Therapeutics|July 17, 2014
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerJosephine Kam Tai Dermawan, Katerina Gurova, John Pink, et al.
Frontiers in Oncology|January 21, 2026
The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti-PD-1 in non-small cell lung cancerC Marcela Diaz-Montero, Elise G Holvey-Bates, Patricia A Rayman, et al.
Breast Cancer Research and Treatment|April 12, 2011
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerMin Han Tan, Sarmishtha De, Gurkan Bebek, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2021
The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damageSarmishtha De, Elise G Holvey-Bates, Kala Mahen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2005
VEGF-integrin interplay controls tumor growth and vascularizationSarmishtha De, Olga Razorenova, Noel Patrick McCabe, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2015
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signalSarmishtha De, Hao Zhou, David DeSantis, et al.
British Journal of Cancer|December 1, 2020
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancerDaniel J Lindner, Gary Wildey, Yvonne Parker, et al.
Blood|April 24, 2004
Impaired platelet responses to thrombin and collagen in AKT-1-deficient miceJuhua Chen, Sarmishtha De, Derek S Damron, et al.
Cancer Research|February 15, 2018
The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing <i>NOTCH1</i> Expression and Targeting Tumor-Initiating CellsSarmishtha De, Daniel J Lindner, Claire J Coleman, et al.
The Journal of Biological Chemistry|July 30, 2003
Molecular pathway for cancer metastasis to boneSarmishtha De, Juhua Chen, Natalya V Narizhneva, et al.
Molecular Cancer Therapeutics|July 17, 2014
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerJosephine Kam Tai Dermawan, Katerina Gurova, John Pink, et al.
Frontiers in Oncology|January 21, 2026
The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti-PD-1 in non-small cell lung cancerC Marcela Diaz-Montero, Elise G Holvey-Bates, Patricia A Rayman, et al.
Breast Cancer Research and Treatment|April 12, 2011
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerMin Han Tan, Sarmishtha De, Gurkan Bebek, et al.
Pageof 3